Login
$ABUS
$4.04 -$0.05 (1.22%) Live

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer Age 2025 pay Source
Lindsay Androski Also a director
President and CEO
Title from the Form 4 dated Oct 1, 2026
49 $1,369,013
Tuan Nguyen
Chief Financial Officer
Title from the Form 4 dated Oct 1, 2026
Not stated $2,416,995

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Average tenure
1.0 years
from year joined
CEO also chairs the board
Yes
Lindsay Androski
Director Age On board Other public boards 2025 pay Source
Lindsay Androski
49 2025
1 year
None stated Paid as CEO
Robert Alan Beardsley
65 2025
1 year
Inflamax, Metallomix, Euclises Pharmaceuticals $417,974
Joseph Bishop
51 2025
1 year
None stated Not stated
Matthew Gline
41 2025
1 year
Datavant Not stated
Roger Sawhney
56 2025
1 year
Actuate Therapeutics, Adlai Nortye, Bobcat Bio $387,961

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 14, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support